The new NICE guidelines for type 2 diabetes - a critical analysis

British Journal of Diabetes and Vascular Disease

Volumn 15, Issue 1, 2015, Pages 3-7

  O'Hare, J Paul ^a   Miller Jones, David ^b   Hanif, Wasim ^c   Hicks, Deborah ^d   Evans, Marc ^e   Leslie, David ^f   Bain, Stephen C ^g   Barnett, Anthony H ^h  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d BARNET ENFIELD AND HARINGEY MENTAL HEALTH NHS TRUST   (United Kingdom)

^e LLANDOUGH HOSPITAL   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g SWANSEA UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INCRETIN; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE;

COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 84963815289     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.15277/bjdvd.2015.006     Document Type: Review

References (19)

1. NICE. Type 2 diabetes: guideline consultation 2015. https://www.nice.org.uk/guidance/gid-cgwave0612/resources/type-2-diabetes-guideline-consultation2 (Accessed January 2015)
2. Khunti, K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self-management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ 2012;344:e2333. http://dx.doi.org/10.1136/bmj.e2333
3. Deakin TA, Cade JE, Wiliams R, Greenwood DC. Structured patient education: the Diabetes X-PERT Programme makes a difference. Diabet Med 2006 23; 9:944-54. http://dx.doi.org/10.1111/j.1464-5491.2006.01906.x
4. Farmer A, Wade A, Goyder E, et al. Impact of self-monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;225:132. http://dx.doi.org/10.1136/bmj.39247.447431. BE
5. Viberti G, Kahan SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicentre study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43. http://dx.doi.org/10.2337/diacare.25.10.1737
6. Leese G P, Wang J, Broomhall J, et al. for the DARTS/MEMO Collaboration. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80. http://dx.doi.org/10.2337/diacare.26.4.1176
7. Rajendran R, Hodgkinson D, Rayman G. Patients with diabetes requiring emergency department care for hypoglycaemia: characteristics and longterm outcomes determined from multiple data sources. Postgrad Med J 2015 (in press). http://dx.doi.org/10.1136/postgradmedj-2014-132926
8. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50; 1140-7. http://dx.doi.org/10.1007/s00125-007-0599-y
9. Shah ZH, Saleem KO. A comparative study of repaglinide and glibenclamide in type 2 diabetic patients. Pakistan J Med Health Sci 2011;5:476-9.
10. Phung OJ, Scholle JM, Talwar M, Coleman CL. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycaemic control, weight gain, and hypoglycaemia in type 2 diabetes. JAMA 2010;303:1410-18. http://dx.doi.org/10.1001/jama.2010.405
11. World Health Organisation. Adherence to long term therapies. Evidence for action. Switzerland, 2003.
12. Just what the doctor ordered: a EU response to medication non-adherence. Tuesday 28 September 2010, Bibliotheque Solvay, Brussels.
13. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26:1408-12. http://dx.doi.org/10.2337/diacare.26.5.1408
14. Khunti K, Davies M. Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes Obes Metab 2010;12:474-84. http://dx.doi.org/10.1111/j.1463-1326.2009.01186.x
15. Robinson LE, Holt TA, Rees K, et al. Effects of GLP-1 agonists on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open 2013;3: pii:e001986. http://dx.doi.org/10.1136/bmjopen-2012-001986
16. Thong KY, Gupta PS, Cull ML, et al. GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice. Br J Diabetes Vasc Dis 2014;14:52-9. http://dx.doi.org/10.15277/bjdvd.2014.015
17. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28. http://dx.doi.org/10/1056/NEJMoa1006524
18. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-92. http://dx.doi.org/10.2337/dc08-9026
19. Inzucchi SE, Berganstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9. http://dx.doi.org/10.2337/dc14-2441